Functional mitral regurgitation (MR) is frequently detected in patients with dilated cardiomyopathy and advanced heart failure, worsening quality of life and predicting poor survival. However, the optimal treatment of patients with advanced heart failure and severe MR has been controversial. We present the case of a 55-year-old man with previous aortic valve replacement, severe MR with high-grade pulmonary hypertension, and refractory heart failure (HF). He was listed for cardiac transplant and underwent percutaneous MitraClip implantation as bridge therapy. The postoperative course was uneventful, with significant improvement in New York Heart Association functional class. The patient underwent a successful heart transplant 8 months after ...
Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip® was shown to be a safe...
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased ri...
MitraClip therapy has been proposed as therapeutic option in selected patients with degenerative or ...
BACKGROUND: Patients awaiting heart transplantation (HTx) often need bridging therapies to reduce wo...
Advanced heart failure (HF) prevalence is increasing and ranges between 1% and 10% of the overall HF...
Secondary mitral valve regurgitation is a frequent consequence of left ventricular dysfunction in pa...
AIMS: To assess the feasibility, short-term durability and clinical outcomes of MitraClip® therap...
Functional mitral regurgitation (FMR) is associated with poor outcomes in patients with heart failur...
Background: Functional mitral regurgitation (FMR) is a common finding among patients with heart fail...
Secondary (or functional) mitral regurgitation (MR) frequently accompanies heart failure syndromes a...
BACKGROUND In the first report from the MitraBridge registry, MitraClip as a bridge to heart tran...
BACKGROUND: Functional mitral regurgitation (FMR) is a common finding among patients with heart fail...
Background The role of percutaneous mitral valve repair (PMVR) in patients with end-stage heart fail...
Background: In the first report from the MitraBridge registry, MitraClip as a bridge to heart transp...
Background: The aim of this study was to investigate long-term survival, clinical status, and echoca...
Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip® was shown to be a safe...
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased ri...
MitraClip therapy has been proposed as therapeutic option in selected patients with degenerative or ...
BACKGROUND: Patients awaiting heart transplantation (HTx) often need bridging therapies to reduce wo...
Advanced heart failure (HF) prevalence is increasing and ranges between 1% and 10% of the overall HF...
Secondary mitral valve regurgitation is a frequent consequence of left ventricular dysfunction in pa...
AIMS: To assess the feasibility, short-term durability and clinical outcomes of MitraClip® therap...
Functional mitral regurgitation (FMR) is associated with poor outcomes in patients with heart failur...
Background: Functional mitral regurgitation (FMR) is a common finding among patients with heart fail...
Secondary (or functional) mitral regurgitation (MR) frequently accompanies heart failure syndromes a...
BACKGROUND In the first report from the MitraBridge registry, MitraClip as a bridge to heart tran...
BACKGROUND: Functional mitral regurgitation (FMR) is a common finding among patients with heart fail...
Background The role of percutaneous mitral valve repair (PMVR) in patients with end-stage heart fail...
Background: In the first report from the MitraBridge registry, MitraClip as a bridge to heart transp...
Background: The aim of this study was to investigate long-term survival, clinical status, and echoca...
Background: Percutaneous edge-to-edge mitral valve repair with the MitraClip® was shown to be a safe...
Patients with severe mitral regurgitation (MR) after myocardial infarction (MI) have an increased ri...
MitraClip therapy has been proposed as therapeutic option in selected patients with degenerative or ...